Company: VRCA
Filing Date: 2025-12-30
Form Type: 3
Source: 0000902664-25-005416
Chunk: 1

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-30
Form: 3
Chunk 1
---
 |   |
| Pre-Funded Warrants (right to buy)         |                                                    $0.00 | N/A                                                                         | N/A                                                    | N/A                                                      | N/A                                                   | N/A | N/A | 11/25/2025 - [F2]       | Common Stock - 4,126,239 | N/A | N/A | I |
| Series C Warrants (right to buy)           |                                                    $6.32 | N/A                                                                         | N/A                                                    | N/A                                                      | N/A                                                   | N/A | N/A | 11/25/2025 - 11/25/2030 | Common Stock - 1,031,559 | N/A | N/A | I |
| Series B Warrants (right to buy)           |                                                   $13.35 | N/A                                                                         | N/A                                                    | N/A                                                      | N/A                                                   | N/A | N/A | 11/22/2024 - 11/22/2029 | Common Stock - 421,346   | N/A | N/A | I |

Remarks:

Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 3 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Each of the Reporting Persons may be deemed to be a director by deputization of Verrica Pharmaceuticals Inc. (the "Issuer") by virtue of the fact that Dr. Charles Frantzreb, a Partner at Caligan, currently serves on the Issuer's board of directors.

| ** Signature of Reporting Person                                 
 /s/ Caligan Partners LP, By: /s/ David Johnson, Managing Partner | Date       
 12/30/2025 |

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. 
 Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.